Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q21098999> ?p ?o }
Showing triples 1 to 62 of
62
with 100 triples per page.
- Q21098999 subject Q7335338.
- Q21098999 subject Q8493060.
- Q21098999 subject Q8878420.
- Q21098999 subject Q9052323.
- Q21098999 abstract "Elagolix (INN, USAN) (former developmental code names NBI-56418, ABT-620) is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM) that is under development for clinical use by Neurocrine Biosciences and AbbVie. As of 2015, it is in phase III clinical trials for the treatment of endometriosis and uterine leiomyoma.[1] The drug was also under investigation for the treatment of prostate cancer and benign prostatic hyperplasia, but development for these indications was ultimately not pursued.[2] Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability.Because of the relatively short half-life of elagolix, the actions of gonadotropin-releasing hormone (GnRH) are not fully blocked throughout the day. For this reason, gonadotropin and sex hormone levels are only partially suppressed, and the degree of suppression can be dose-dependently adjusted, as desired. Moreover, if elagolix is discontinued, its effects are rapidly reversible. Due to the suppression of estrogen levels by elagolix being incomplete, effects on bone mineral density are minimal, which is in contrast to first-generation GnRH inhibitors. Moreover, the incidence and severity of menopausal side effects such as hot flashes are also reduced relative to first-generation GnRH inhibitors.".
- Q21098999 atcPrefix "H01".
- Q21098999 atcSuffix "CC02".
- Q21098999 casNumber "834153-87-6".
- Q21098999 casSupplemental "832720-36-2 (sodium)".
- Q21098999 iupacName "4-(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid".
- Q21098999 pubchem "11250647".
- Q21098999 thumbnail Elagolix_structure.png?width=300.
- Q21098999 wikiPageExternalLink 800020238.
- Q21098999 wikiPageExternalLink pipeline.html.
- Q21098999 wikiPageExternalLink elagolix-gnrh-antagonist.
- Q21098999 wikiPageWikiLink Q14662364.
- Q21098999 wikiPageWikiLink Q14864006.
- Q21098999 wikiPageWikiLink Q177708.
- Q21098999 wikiPageWikiLink Q181257.
- Q21098999 wikiPageWikiLink Q1858291.
- Q21098999 wikiPageWikiLink Q1988322.
- Q21098999 wikiPageWikiLink Q205764.
- Q21098999 wikiPageWikiLink Q21099000.
- Q21098999 wikiPageWikiLink Q21099001.
- Q21098999 wikiPageWikiLink Q2304401.
- Q21098999 wikiPageWikiLink Q277954.
- Q21098999 wikiPageWikiLink Q285166.
- Q21098999 wikiPageWikiLink Q30612.
- Q21098999 wikiPageWikiLink Q3269441.
- Q21098999 wikiPageWikiLink Q3618379.
- Q21098999 wikiPageWikiLink Q3931280.
- Q21098999 wikiPageWikiLink Q409770.
- Q21098999 wikiPageWikiLink Q422812.
- Q21098999 wikiPageWikiLink Q461809.
- Q21098999 wikiPageWikiLink Q47270.
- Q21098999 wikiPageWikiLink Q4926095.
- Q21098999 wikiPageWikiLink Q506659.
- Q21098999 wikiPageWikiLink Q556281.
- Q21098999 wikiPageWikiLink Q658.
- Q21098999 wikiPageWikiLink Q7002174.
- Q21098999 wikiPageWikiLink Q7180990.
- Q21098999 wikiPageWikiLink Q7335338.
- Q21098999 wikiPageWikiLink Q824258.
- Q21098999 wikiPageWikiLink Q8493060.
- Q21098999 wikiPageWikiLink Q8878420.
- Q21098999 wikiPageWikiLink Q9052323.
- Q21098999 wikiPageWikiLink Q905999.
- Q21098999 wikiPageWikiLink Q9635.
- Q21098999 atcPrefix "H01".
- Q21098999 atcSuffix "CC02".
- Q21098999 casNumber "834153".
- Q21098999 casSupplemental "832720".
- Q21098999 iupacName "4".
- Q21098999 pubchem "11250647".
- Q21098999 type ChemicalSubstance.
- Q21098999 type Drug.
- Q21098999 type ChemicalObject.
- Q21098999 type Thing.
- Q21098999 type Q8386.
- Q21098999 comment "Elagolix (INN, USAN) (former developmental code names NBI-56418, ABT-620) is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM) that is under development for clinical use by Neurocrine Biosciences and AbbVie.".
- Q21098999 label "Elagolix".
- Q21098999 depiction Elagolix_structure.png.